Impact of vector copy number on critical quality attributes of retrovirally engineered T cells.

ABSTRACT: Genetically engineered T cell therapies are approved by the FDA for the treatment of various cancers. The cell products in these treatments are manufactured using retroviral vectors to insert an antigen-targeting receptor into the T cell genome. Limited data exist on how vector copy number (VCN) per transduced cell impacts critical quality attributes (CQAs) of retrovirally engineered T cell products. We investigated the effect of VCN on the purity and potency of E7 T cells, a T cell receptor (TCR)-engineered cell product that has shown safety and clinical activity in human papillomavirus (HPV)-associated cancers. An increased VCN correlated with enhanced functional characteristics, including transduction efficiency, tumor recognition as measured by IFN-γ production, and cytotoxic activity

SUBMITTER: Norberg SM 

PROVIDER: S-EPMC12817206 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature